Oruka Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Oruka Therapeutics, Inc. (ORKA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-91.34-5.34-9.93-19.32-9.74-5.48-7.93
Depreciation & Amortization0.030.110.110.090.090.090.02
Stock Based Compensation16.280.000.000.000.000.000.00
Change in Working Capital12.64-0.40-0.91-0.141.190.46-0.61
Change in Accounts Payable10.350.000.000.000.000.000.00
Change in Other Working Capital2.300.000.000.000.000.000.00
Other Operating Activities1.740.690.560.500.040.150.00
Net Cash from Operating Activities-63.09-5.01-10.91-18.76-7.73-4.80-8.24
Investing Activities
Capital Expenditures-0.210.000.000.040.020.000.00
Purchases of Investments-359.930.000.000.000.000.000.00
Sales/Maturities of Investments0.000.000.000.000.000.003.05
Net Cash from Investing Activities-360.140.000.00-0.04-0.020.003.05
Financing Activities
Debt Repayment0.000.000.000.00-0.41-0.350.00
Common Stock Issued454.570.000.0024.0750.897.283.53
Other Financing Activities5.390.000.00-0.98-2.03-0.37-0.43
Net Cash from Financing Activities490.410.000.0023.0948.456.563.10
Summary
Effect of Forex Changes on Cash-37.430.000.000.000.000.000.00
Net Change in Cash67.17-5.01-10.914.2940.711.76-2.09
Cash at Beginning of Period37.4342.4553.3649.078.366.618.70
Cash at End of Period61.5837.4342.4553.3649.078.366.61
Free Cash Flow-63.30-5.01-10.91-18.81-7.74-4.81-8.25
Supplemental Disclosures
Interest Paid0.000.000.000.000.010.010.01